The 3 T’s: Positioning Ireland for FDI
What makes Ireland attractive for FDI? As the former general manager of Genzyme’s Waterford site, Pat O’Sullivan explains that a longstanding 12.5% corporate tax rate (that isn’t going anywhere)…
What makes Ireland attractive for FDI? As the former general manager of Genzyme’s Waterford site, Pat O’Sullivan explains that a longstanding 12.5% corporate tax rate (that isn’t going anywhere)…
Lilly set up in Ireland three decades ago by purchasing a farm. In its early days, the operation produced intermediaries for small-molecule drugs. Nearby, Pfizer was manufacturing citric acid for…
It is widely acknowledged that pharmaceutical manufacturing operations have entered into a period of significant cost reduction. Service providers like Dalkia—a French energy services company that has built its Irish…
“The government’s vision has always been for indigenous companies to develop from the expertise brought in by FDI—and we are seeing that happening now.” Joe Costello, Minister for Trade &…
“The elements that have made Ireland attractive for decades are still here. The big difference since 2007, however, is the cost base. If you are building a pharma plant…
Kells Stainless, founded in 1988, is celebrating 25 years this year. Looking back, what have been the company’s principal achievements over these decades? Originally, Kells Stainless was set up to…
Mr. Murphy, you first joined PM Group 24 years ago. How has the company, and the market, changed? My background, prior to joining PM Group, was in the pharmaceutical industry—I…
Mr. O’Sullivan, can you please begin with a brief introduction to the Genzyme Waterford site? Genzyme Waterford was set up in 2001, to support the manufacture of drug products for…
Mr. O’Sullivan, can you please begin with a brief introduction to the Genzyme Waterford site? Genzyme Waterford was set up in 2001, to support the manufacture of drug products for…
Fergal Murphy, Chairman of the Association of Pharmaceutical Manufacturers in Ireland, discusses with pharamaboardroom.com the difficulties in such a small market and how the industry is adapting to the needs…
Mr. Egan, what path led you to IMS Health? My original background is in science—I received a PhD in medical microbiology, and worked for some time as a post-doctoral researcher…
Can you please introduce yourself, and Ernst & Young’s life science practice in Ireland, to our readers? I am the managing partner of Ernst & Young (EY) in Ireland, responsible…
See our Cookie Privacy Policy Here
